RU2622644C2 - Кристаллическое вещество и содержащий его фармацевтический препарат - Google Patents
Кристаллическое вещество и содержащий его фармацевтический препарат Download PDFInfo
- Publication number
- RU2622644C2 RU2622644C2 RU2015113638A RU2015113638A RU2622644C2 RU 2622644 C2 RU2622644 C2 RU 2622644C2 RU 2015113638 A RU2015113638 A RU 2015113638A RU 2015113638 A RU2015113638 A RU 2015113638A RU 2622644 C2 RU2622644 C2 RU 2622644C2
- Authority
- RU
- Russia
- Prior art keywords
- crystalline substance
- crystalline
- pharmaceutical preparation
- luliconazole
- present
- Prior art date
Links
- 239000000126 substance Substances 0.000 title claims abstract description 111
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 43
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 121
- YTAOBBFIOAEMLL-REQDGWNSSA-N Luliconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@H](CS\1)SC/1=C(\C#N)N1C=NC=C1 YTAOBBFIOAEMLL-REQDGWNSSA-N 0.000 claims abstract description 56
- 229960000570 luliconazole Drugs 0.000 claims abstract description 56
- 241000233866 Fungi Species 0.000 claims abstract description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 28
- 238000001953 recrystallisation Methods 0.000 claims description 25
- 239000002904 solvent Substances 0.000 claims description 18
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 239000002178 crystalline material Substances 0.000 claims description 10
- 230000006866 deterioration Effects 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000012937 correction Methods 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000002270 dispersing agent Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 11
- 238000004090 dissolution Methods 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 230000000052 comparative effect Effects 0.000 description 19
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 11
- 208000002474 Tinea Diseases 0.000 description 10
- 239000013078 crystal Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 238000001914 filtration Methods 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 206010012504 Dermatophytosis Diseases 0.000 description 5
- 206010017533 Fungal infection Diseases 0.000 description 5
- 241001460074 Microsporum distortum Species 0.000 description 5
- 208000031888 Mycoses Diseases 0.000 description 5
- 241000224526 Trichomonas Species 0.000 description 5
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 229960004592 isopropanol Drugs 0.000 description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 5
- 208000007163 Dermatomycoses Diseases 0.000 description 4
- 208000035415 Reinfection Diseases 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 206010067409 Trichophytosis Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000003929 dermatomycosis Diseases 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- 206010005913 Body tinea Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000010410 Nogo Proteins Human genes 0.000 description 1
- 108010077641 Nogo Proteins Proteins 0.000 description 1
- 208000007712 Tinea Versicolor Diseases 0.000 description 1
- 206010056131 Tinea versicolour Diseases 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 239000012526 feed medium Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 201000000508 pityriasis versicolor Diseases 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000013097 stability assessment Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000003875 tinea corporis Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012202514 | 2012-09-14 | ||
| JP2012-202514 | 2012-09-14 | ||
| JP2013-131504 | 2013-06-24 | ||
| JP2013131504 | 2013-06-24 | ||
| PCT/JP2013/074775 WO2014042231A1 (en) | 2012-09-14 | 2013-09-06 | Crystal and pharmaceutical preparation containing the same crystal |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015113638A RU2015113638A (ru) | 2016-11-10 |
| RU2622644C2 true RU2622644C2 (ru) | 2017-06-19 |
Family
ID=49237577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015113638A RU2622644C2 (ru) | 2012-09-14 | 2013-09-06 | Кристаллическое вещество и содержащий его фармацевтический препарат |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9012484B2 (enExample) |
| EP (1) | EP2895165B1 (enExample) |
| JP (1) | JP5589130B1 (enExample) |
| CN (1) | CN104284662A (enExample) |
| IN (1) | IN2015DN02929A (enExample) |
| RU (1) | RU2622644C2 (enExample) |
| WO (1) | WO2014042231A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102387785B (zh) | 2009-04-09 | 2017-08-25 | 宝丽制药股份有限公司 | 抗真菌药物组合物 |
| CN102387786B (zh) | 2009-04-09 | 2015-09-09 | 宝丽制药股份有限公司 | 抗真菌药物组合物 |
| US8952044B2 (en) | 2009-08-25 | 2015-02-10 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
| WO2011155640A1 (en) | 2010-06-11 | 2011-12-15 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
| CN104619704B (zh) | 2012-09-14 | 2017-12-05 | 宝丽制药股份有限公司 | 表面自由能用于分化评价晶体的用途，基于表面自由能作为指标评价的晶体，以及通过包含所述晶体制备的药物组合物 |
| US9199977B2 (en) | 2012-09-14 | 2015-12-01 | Pola Pharma Inc. | Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal |
| JP5460797B1 (ja) | 2012-09-14 | 2014-04-02 | 株式会社ポーラファルマ | アミド誘導体及び安定性指標としてのその使用 |
| JP5589110B1 (ja) | 2013-03-08 | 2014-09-10 | 株式会社ポーラファルマ | 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物 |
| JP5680161B1 (ja) * | 2013-09-06 | 2015-03-04 | 株式会社ポーラファルマ | 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物 |
| JP5587488B1 (ja) | 2013-12-12 | 2014-09-10 | 株式会社ポーラファルマ | ルリコナゾールを含有する製剤の評価方法及び指標物質 |
| US10703744B2 (en) | 2014-12-12 | 2020-07-07 | Glenmark Life Sciences Limited | Process for preparation of luliconazole |
| JP5951864B1 (ja) * | 2015-06-05 | 2016-07-13 | 株式会社ポーラファルマ | 抗ジアルジア剤 |
| JP2017101009A (ja) | 2015-12-04 | 2017-06-08 | 株式会社ポーラファルマ | 抗アカントアメーバ剤及びその製造法 |
| TR201714882A2 (tr) | 2017-10-03 | 2019-04-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Luli̇konazolün topi̇kal farmasöti̇k kompozi̇syonlari |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997002821A2 (en) * | 1995-07-08 | 1997-01-30 | Nihon Nohyaku Co., Ltd. | Antifungal agent, compound therefor, process for producing the same |
| WO2007102241A1 (ja) * | 2006-03-08 | 2007-09-13 | Nihon Nohyaku Co., Ltd. | 外用の医薬組成物 |
| RU2008139904A (ru) * | 2006-03-08 | 2010-04-20 | Нихон Нохияку Ко.,Лтд. (Jp) | Фармацевтическая композиция для наружного применения |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3081766B2 (ja) | 1994-05-06 | 2000-08-28 | 東興薬品工業株式会社 | 角質貯留型抗真菌外用組成物 |
| JP3278738B2 (ja) | 1995-07-08 | 2002-04-30 | 日本農薬株式会社 | 抗真菌剤 |
| JP2002114680A (ja) | 2000-07-31 | 2002-04-16 | Nippon Nohyaku Co Ltd | 抗真菌剤 |
| PL2005958T3 (pl) | 2006-03-08 | 2013-11-29 | Nihon Nohyaku Co Ltd | Kompozycja farmaceutyczna do stosowania zewnętrznego |
| KR20100075475A (ko) | 2007-09-05 | 2010-07-02 | 가부시키가이샤 폴라 파마 | 의약 조성물 |
| KR20100075476A (ko) | 2007-09-05 | 2010-07-02 | 가부시키가이샤 폴라 파마 | 항진균 조성물 |
| HUE030028T2 (en) * | 2007-09-05 | 2017-04-28 | Pola Pharma Inc | Antifungal drug |
| ES2468540T3 (es) | 2009-02-13 | 2014-06-16 | Topica Pharmaceuticals, Inc | Formulación antif�ngica |
| CN102387785B (zh) | 2009-04-09 | 2017-08-25 | 宝丽制药股份有限公司 | 抗真菌药物组合物 |
| CN102387786B (zh) | 2009-04-09 | 2015-09-09 | 宝丽制药股份有限公司 | 抗真菌药物组合物 |
| US8952044B2 (en) | 2009-08-25 | 2015-02-10 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
| WO2011155640A1 (en) | 2010-06-11 | 2011-12-15 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
| US8728210B2 (en) | 2011-07-07 | 2014-05-20 | Hsueh Yuan Lee | Exhaust gas treatment apparatus and method |
| CN103012385B (zh) * | 2012-02-17 | 2015-07-08 | 山东威智医药工业有限公司 | 卢立康唑的晶型及其制备方法 |
| CN104619320A (zh) | 2012-09-14 | 2015-05-13 | 宝丽制药股份有限公司 | 含有卢立康唑的药物组合物 |
| JP5460797B1 (ja) | 2012-09-14 | 2014-04-02 | 株式会社ポーラファルマ | アミド誘導体及び安定性指標としてのその使用 |
| US9199977B2 (en) | 2012-09-14 | 2015-12-01 | Pola Pharma Inc. | Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal |
| CN104619704B (zh) | 2012-09-14 | 2017-12-05 | 宝丽制药股份有限公司 | 表面自由能用于分化评价晶体的用途，基于表面自由能作为指标评价的晶体，以及通过包含所述晶体制备的药物组合物 |
| JP5589110B1 (ja) | 2013-03-08 | 2014-09-10 | 株式会社ポーラファルマ | 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物 |
-
2013
- 2013-09-06 US US14/019,997 patent/US9012484B2/en active Active
- 2013-09-06 JP JP2013185320A patent/JP5589130B1/ja active Active
- 2013-09-06 CN CN201380018386.2A patent/CN104284662A/zh active Pending
- 2013-09-06 EP EP13766723.4A patent/EP2895165B1/en active Active
- 2013-09-06 WO PCT/JP2013/074775 patent/WO2014042231A1/en not_active Ceased
- 2013-09-06 IN IN2929DEN2015 patent/IN2015DN02929A/en unknown
- 2013-09-06 RU RU2015113638A patent/RU2622644C2/ru active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997002821A2 (en) * | 1995-07-08 | 1997-01-30 | Nihon Nohyaku Co., Ltd. | Antifungal agent, compound therefor, process for producing the same |
| WO2007102241A1 (ja) * | 2006-03-08 | 2007-09-13 | Nihon Nohyaku Co., Ltd. | 外用の医薬組成物 |
| RU2008139904A (ru) * | 2006-03-08 | 2010-04-20 | Нихон Нохияку Ко.,Лтд. (Jp) | Фармацевтическая композиция для наружного применения |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5589130B1 (ja) | 2014-09-10 |
| RU2015113638A (ru) | 2016-11-10 |
| US20140080882A1 (en) | 2014-03-20 |
| JP2015027972A (ja) | 2015-02-12 |
| EP2895165B1 (en) | 2016-12-14 |
| IN2015DN02929A (enExample) | 2015-09-18 |
| EP2895165A1 (en) | 2015-07-22 |
| WO2014042231A1 (en) | 2014-03-20 |
| CN104284662A (zh) | 2015-01-14 |
| US9012484B2 (en) | 2015-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2622644C2 (ru) | Кристаллическое вещество и содержащий его фармацевтический препарат | |
| RU2603963C2 (ru) | Кристалл, обладающий кристаллическими габитусами, и фармацевтическая композиция, полученная обработкой данного кристалла | |
| CN105026390B (zh) | 具有特异性结晶习性的晶型以及含有作为活性成分的该晶型的药物组合物 | |
| CN117551030A (zh) | N-(4-(4-(环丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺酰胺的结晶形式 | |
| AU2014329421A1 (en) | Stabilized efinaconazole compositions | |
| US11173142B2 (en) | Cancer treatment composition | |
| CN102784382B (zh) | 一种阿加曲班药物组合物及其制备方法和应用 | |
| CN103553996B (zh) | 抗胆碱药物组合物 | |
| EP3041837B1 (en) | Crystal having specific crystal habit and pharmaceutical composition containing the crystal as active ingredient | |
| JP5795694B2 (ja) | 結晶及び該結晶を含有してなる医薬製剤 | |
| CN110269854A (zh) | 桑根酮c的医药新用途 | |
| JP5795693B2 (ja) | 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物 | |
| EP3057571A1 (en) | Proton pump inhibitor paste compositions | |
| CN110711174A (zh) | 一种泊沙康唑注射液中间体溶液配制方法 | |
| HK40007140A (en) | Topical composition comprising terbinafine and preparation method thereof | |
| CN110964061A (zh) | 一种注射用福司氟康唑的精制方法 |